PPD picks up Bioclinica’s global site business

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/utah778)
(Image: Getty/utah778)

Related tags Ppd AES Patient recruitment Clinical trial sites

The acquisition of Bioclinica’s clinical research site business extends PPD’s trial enrollment business to five continents, 20 countries, and more than 180 research sites.

PPD’s ​Accelerated Enrollment Solutions (AES) business unit today acquired the clinical research site business of Bioclinica.

“This acquisition further strengthens our ability to rapidly recruit patients and seamlessly execute trials,”​ Roger Smith, senior vice president and general manager of Accelerated Enrollment Solutions (AES), told us, adding that the company’s goal is to have the resources on hand to deliver larger, more diverse client projects.

Smith called the acquisition ‘an important step’ toward meeting this goal, as it adds new sites and ‘opens key markets’ for AES in China, Latin America, and Western Europe.

The deal also bolsters the company’s presence in North America, Europe, and South Africa, and provides dedicated research sites in Florida with ‘significant’ neuroscience expertise. Of the four FL-based sites, one is dedicated to Phase I trials and will move to PPD’s early development team.

“Bringing these new sites on board under AES strengthens our ability to execute, manage, and budget our clients’ trials with greater precision and advances our strategy of becoming the world’s largest patient access and site conduct organization,”​ added Smith. The new sites also present opportunities to grow the business in new therapeutic areas.

“We also will continue to enhance variations of the core services we can support with these sites to meet the specific needs of our clients, particularly at the indication level … and based on geographic considerations,”​ Smith said.

Financial details were not disclosed.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more